Logo
Whalesbook
HomeNewsCorporate NewsPremiumStocks
HomeNewsCorporate NewsPremiumStocks

Glenmark Pharmaceuticals Ltd

₹ 2,0110.15%
14 Jan – close price
🔗glenmarkpharma.com•BSE: 532296•NSE: GLENMARK
Market Cap₹ 56,759 Cr.
Current Price₹ 2,011
High / Low₹ 2,286
Stock P/E38.6
Book Value₹ 848
Dividend Yield0.12 %
ROCE9.72 %
ROE7.35 %
Face Value₹ 1.00
Sales₹ 8,194 Cr.
OPM16.9 %
Mar Cap₹ 56,759 Cr.

ABOUT

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.[1]

KEY POINTS

Leadership[1]<h1>14th largest and fastest growing in the Indian market</h1><h1>15th largest generic company by prescriptions filled in the USA</h1><h1>5th largest Indian generic co. in Europe.</h1>

Also present in buckets:
Aggressive Growth TriggersExcellent ResultsRevenue GuidanceAsset Base ExpansionCapacity Expansion And ProductsJv Partnerships AcquisitionsCredit Rating UpdatesRed Flags And Poor Performance

Peer Comparision

S.No.NameCurrent Price (Rs.)Price to EarningMarket Capitalization (Rs.Cr.)Dividend yield (%)Net Profit latest quarter (Rs.Cr.)YOY Quarterly profit growth (%)Sales latest quarter (Rs.Cr.)YOY Quarterly sales growth (%)Return on capital employed (%)Sales (Rs.Cr.)OPM (%)Profit after tax (Rs.Cr.)Profit after tax latest quarter (Rs.Cr.)Price to book valueReturn on assets (%)Debt to equity
1.Sun Pharma.Inds.1700.7035.35408054.900.943124.952.5614478.318.9320.2154964.0130.1211543.963117.955.2412.970.07
2.Divi's Lab.6355.5067.89168718.560.47689.0035.102715.0016.1220.4410029.0032.372485.00689.0010.9513.530.01
3.Torrent Pharma.4003.7062.54135503.400.80591.0032.493302.0014.3027.0512248.0032.602166.53600.1716.0413.260.33
4.Cipla1434.5021.30115874.780.911353.373.737589.447.6422.7228349.5725.405441.141351.173.5214.720.01
5.Lupin2195.9023.19100308.450.551484.8373.347047.5124.2321.3024750.6927.254324.631477.925.1112.410.32
6.Dr Reddy's Labs1186.5017.1699028.890.671336.807.288828.309.8322.6934310.0024.645772.201347.102.7512.950.16
7.Mankind Pharma2244.4052.9992649.970.04520.18-22.003697.1620.7715.9813545.6724.121748.55511.516.068.890.55
8.Glenmark Pharma.2011.3038.5856759.050.12-739.19-67.631538.66-41.639.728194.3716.901471.26192.602.376.290.02
–Median: 149 Co.394.529.81738.640.1212.5710.46161.7610.5414.8591.7315.9345.2613.963.098.210.22

Quarterly Results

Standalone figures in ₹ crores

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales
1,9122,2082,1611,9392,1442,2331,3652,1482,3302,6362,2512,0102,3951,539
Expenses
1,4781,8261,7231,7211,6591,7901,5491,6511,6981,8571,7571,6691,6671,717
Operating Profit
434382439218485443-184497631779494341728-178
Other Income
347317252-42518542345,9335683129-91-254-646
Profit before tax
696601589-313392389-766,295618795559181401-906
Tax %
29%30%27%-56%31%22%-73%27%27%25%26%18%18%-18%
Net Profit
493423430-137272302-204,614454595414148330-739
EPS in Rs
17.4615.0015.26-4.879.6310.72-0.72163.5016.0821.0914.665.2411.70-26.19

Profit & Loss

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales
2,3015,0866,1157,9895,5206,3056,7137,5688,1428,2217,8919,2268,194
Expenses
1,8053,6184,3495,0894,4174,9775,4075,6766,4536,7486,6496,9826,810
Operating Profit
4961,4671,7662,9001,1031,3281,3051,8921,6891,4731,2422,2441,385
Other Income
67-86116-893269546244691,0444906,238177-861
Interest
3130361531912242562662362072774960
Depreciation
3011910010596106139151160184202219227
Profit before tax
5021,2321,7472,5531,1431,9521,5351,9442,3371,5727,0012,154235
Net Profit
4341,0081,4842,1411,0141,6221,3551,6491,9981,2095,1671,610153
EPS in Rs
15.9937.1452.6075.8635.9557.4948.0158.4670.8042.84183.1257.075.41
Dividend Payout %
12%5%4%3%6%3%5%4%4%6%1%4%–

Compounded Sales Growth

10 Years:6%
5 Years:7%
3 Years:4%
TTM:-3%

Compounded Profit Growth

10 Years:4%
5 Years:5%
3 Years:2%
TTM:-22%

Stock Price CAGR

10 Years:10%
5 Years:31%
3 Years:69%
1 Year:38%

Return on Equity

10 Years:11%
5 Years:9%
3 Years:8%
Last Year:7%

Balance Sheet

Standalone figures in ₹ crores

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
27272828282828282828282828
Reserves
2,8794,9257,3389,40810,36311,91413,19814,78116,71017,84922,94224,47623,911
Borrowings
3534107872,7772,9813,1343,5743,7043,7383,221707830476
Other Liabilities
9702,2891,9601,7871,8922,0662,1522,1042,4383,4873,7362,7003,969
Total Liabilities
4,2307,65110,11314,00115,26517,14318,95220,61822,91424,58627,41428,03328,384
Fixed Assets
4491,2311,4381,5961,6991,4131,6121,7221,7521,7461,7561,9792,013
Gross Block
6581,8022,1072,3692,5822,2602,5952,8493,0263,1843,3933,743–
Accumulated Depreciation
2105716697728838479831,1261,2741,4381,6361,764–
CWIP
83294276271420286200131109172198155168
Investments
1,4091,6601,8581,8673,2133,2694,7146,9908,55910,33412,96515,19515,202
Other Assets
2,2894,4666,54110,2679,93312,17412,42611,77412,49412,33412,49610,70511,001
Total Assets
4,2307,65110,11314,00115,26517,14318,95220,61822,91424,58627,41428,03328,384

Cash Flows

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity
1141453558781,1242,4901,5791,2431,2161,474-495589
Cash from Investing Activity
211-176-1,545-2,580-1,137-2,256-1,607-1,235-897-4323,197-490
Cash from Financing Activity
-385-321,2231,879-62-155-139-81-305-978-2,666-95
Net Cash Flow
-60-6432177-7579-168-731464353

Ratios

Standalone Figures in ₹ Crores / Yearly

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days
180175182177253121100120120111115101
Inventory Days
12616118217219514111594102117130156
Days Payable
337343306221273258217201208225307242
Cash Conversion Cycle
-31-6591291754-314143-6215
Working Capital Days
427910817023215110611542291255
ROCE %
17%33%26%29%10%13%11%12%11%11%10%10%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters
46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.64%46.64%46.65%
FIIs
23.19%22.47%25.51%24.79%23.71%21.38%20.98%23.05%23.51%23.15%20.62%20.73%19.20%
DIIs
10.69%10.40%9.10%10.31%10.92%13.36%13.93%13.21%13.85%14.60%17.64%18.61%20.09%
Public
19.45%20.46%18.70%18.21%18.70%18.58%18.42%17.06%15.96%15.56%15.05%13.97%14.02%

* The classifications might have changed from Sep'2022 onwards.ℹ️

BSE Announcements AI Summary

Direct from BSE filings, auto-summarised

Glenmark Pharma Secures US FDA Approval for Progesterone Vaginal Inserts

9th April 2026, 2:21 pm

RPG Life Sciences Opens Demat Window; Pharma Stocks Show Resilience Amidst Tariff Risks

7th April 2026, 11:59 pm

Indian Pharma Sector Shows Resilience Amidst Tariff Concerns, Selective Growth Predicted

7th April 2026, 9:07 pm

Genus Power Informs on Postal Ballot & E-Voting Particulars Dispatch

7th April 2026, 6:06 pm

Glenmark Pharmaceuticals to Appeal GST Demand of ₹16.05 Crore

2nd April 2026, 12:35 am

Published by Other Websites

External media mentions & references

Novo Nordisk Holds Ground: Semaglutide Generics Flood India, Sales Stabilize

16th April 2026, 5:32 pm

Nifty Eyes 24,600 as SBI, Glenmark, Tata Power Rise

16th April 2026, 6:44 am

Nomura Cheers Pharma: Cipla, Sun Pharma Rated 'Buy' on GLP-1 Boom

15th April 2026, 12:47 pm

Novo Patent Loss Triggers Generic 'Gold Rush' in India's Weight-Loss Drug Market

9th April 2026, 3:03 pm

Glenmark Pharma Secures USFDA Nod for Progesterone Inserts, Targets $59M Market

9th April 2026, 12:07 pm

News Articles

Editorial & research coverage

Glenmark Pharma: Motilal Oswal Sees Rs 2,240 Target
Glenmark Pharma: Motilal Oswal Sees Rs 2,240 Target

4th February 2026, 3:00 pm

Glenmark Pharma's Q3 Results: Margin Squeeze Fuels 'Sell' Call
Glenmark Pharma's Q3 Results: Margin Squeeze Fuels 'Sell' Call

4th February 2026, 12:57 pm

Glenmark Pharma: GST Probe Looms Over Strong Q3 Results
Glenmark Pharma: GST Probe Looms Over Strong Q3 Results

1st February 2026, 4:15 am

Glenmark Pharma Posts Strong Q3 on Broad Growth, Margin Surge
Glenmark Pharma Posts Strong Q3 on Broad Growth, Margin Surge

30th January 2026, 8:50 pm

India's Earnings Season Kicks Off Amid Market Volatility
India's Earnings Season Kicks Off Amid Market Volatility

24th January 2026, 11:15 am

Documents

Announcements

Announcement Under Regulation 30 Of The SEBI (LODR)

5 Jan - SES ESG assigned Glenmark ESG rating 71.1 for FY2025; company has not engaged SES ESG.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

23 Dec - Glenmark launches Epinephrine Injection USP 30mg/30mL multi-dose vial in US; market ~$67.6M (12 months to Oct 2025).

Announcement under Regulation 30 (LODR)-Press Release / Media Release

16 Dec - Exclusive multi-region license for Aumolertinib; upfront low-double-digit million USD; possible >US$1bn milestones

Announcement under Regulation 30 (LODR)-Press Release / Media Release

11 Dec 2025 - Glenmark to launch Leucovorin Calcium Injection 350mg vial in US; distribution begins December 2025; market ~$16.8M.

Update On The Company''s Chhatrapati Sambhajinagar (Aurangabad) Facility

1 Dec 2025 - US FDA pre-approval inspection at Aurangabad (Nov 24–28, 2025) concluded with zero 483 observations.

Annual Reports

Financial Year 2025

(from bse)

Financial Year 2024

(from bse)

Financial Year 2023

(from bse)

Financial Year 2022

(from bse)

Financial Year 2021

(from bse)

Financial Year 2020

(from bse)

Financial Year 2019

(from bse)

Financial Year 2018

(from bse)

Financial Year 2017

(from bse)

Financial Year 2016

(from bse)

Financial Year 2015

(from bse)

Financial Year 2014

(from bse)

Financial Year 2013

(from nse)

Financial Year 2013

(from bse)

Financial Year 2012

(from bse)

Credit Ratings

Rating update

18 Sep 2025 from crisil

Rating update

23 Jul 2025 from fitch

Rating update

18 Jun 2025 from crisil

Rating update

25 Apr 2024 from fitch

Rating update

25 Apr 2024 from fitch

Rating update

20 Mar 2024 from crisil

Concalls

Nov 2025

TranscriptPPTRecording

Aug 2025

TranscriptPPT

Jul 2025

PPT

May 2025

TranscriptPPT

Feb 2025

TranscriptPPT

Nov 2024

TranscriptPPT

Aug 2024

TranscriptPPT

Jun 2024

TranscriptPPT

May 2024

TranscriptPPT

Feb 2024

TranscriptPPTRecording

Nov 2023

TranscriptPPTRecording

Sep 2023

PPT

Aug 2023

TranscriptPPTRecording

May 2023

TranscriptPPT

Feb 2023

TranscriptPPT

Nov 2022

TranscriptPPT

Nov 2022

PPT

Aug 2022

TranscriptPPT

May 2022

TranscriptPPT

Feb 2022

PPT

Nov 2021

PPT

Aug 2021

PPT

May 2021

PPT

Jan 2019

PPT

Jan 2017

PPT

Dec 2016

PPT

Jul 2016

PPT

Jan 2016

PPT

Stock Analysis

Description

  1. Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.

Key Growth Triggers

  1. Currently no data available for Key Growth Triggers.

Order Book

  1. Currently no data available for Order Book.

Key Red Flags

  1. Currently no data available for Key Red Flags.

Key Dates To Watch

  1. Currently no data available for Key Dates To Watch.

Corporate Announcements

9th Apr 26
Impact Rating: 8
Glenmark Pharmaceuticals announced US FDA final approval for Progesterone Vaginal Inserts, 100 mg. This bioequivalent drug targets the US market, which had annual sales of $59.2 million for similar products.
7th Apr 26
Impact Rating: -
No description available.
7th Apr 26
Impact Rating: -
No description available.
7th Apr 26
Impact Rating: -
No description available.
1st Apr 26
Impact Rating: 6
Glenmark Pharmaceuticals is challenging a ₹16.05 crore GST demand, comprising interest and penalty, for FY 2019-20 and 2020-21. The company disputes the demand and expects no material impact.